

AMENDMENTS TO THE CLAIMS

1. (original): Derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with at least one covalently bonded acid, and the salts, solvates and prodrugs thereof.

2. (original): Derivative according to Claim 1, characterised in that the acid is covalently bonded via the 3-hydroxypyrrolidine group of the N-methyl-N-[(1 S)-1 phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide.

3. (currently amended): Derivative according to Claim 1, characterised in that the acid is a selected from physiologically tolerated acid[[s]].

4. (currently amended): Derivative according to Claim 1, characterised in that the acid is selected from the group consisting of carboxylic acids, hydroxycarboxylic acids and inorganic oxygen acids.

5. (previously presented): Derivative according to Claim 1, characterised in that the derivative contains at least one acid function which is capable of salt formation or an acid function which is in the form of a salt.

6. (currently amended): Derivative according to Claim 1, characterised in that the acid is selected from the group consisting of dibasic carboxylic acids, monobasic hydroxycarboxylic acids and dibasic inorganic oxygen acids.

7. (currently amended): Derivative according to Claim 6, characterised in that the monobasic hydroxycarboxylic acid is a selected from sugar acid[[s]].

8. (original): Derivative according to Claim 7, characterised in that the sugar acid is glucuronic acid.

9. (original): Derivative according to Claim 6, characterised in that the dibasic inorganic oxygen acid is sulfuric acid.

10. (currently amended): Derivative according to Claim 1, selected from the group consisting of 6-(1-([(2,2diphenylethanoyl)methylamino]phenylethyl} pyrrolidin-3-yloxy pyrrolidin-3-yloxy}-3,4,5-tri-hydroxytetrahydropyrarr-2-carboxylic acid, mono-{1[2-(diphenylacetyl-methylamino)-2phenylethyl]pyrrolidin-3-yl} sulfate and N-{2-[(3S)-3-acetoxy-1-pyrrolidinyl]-(1S)-1-phenylethyl}-2,2-diphenyl-N-methylacetamide, and salts, solvates, and prodrugs thereof.

11. (previously presented): Derivative according to Claim 1 and/or a salt, solvate or prodrug thereof as medicament.

12. (canceled)

13. (currently amended): ~~The method of claim 12~~ A method of treating or preventing a disease comprising administering an effective dose of the derivative, salt, solvate, or prodrug of claim 1 to a subject in need thereof, wherein the disease is selected from the group consisting of a gastrointestinal tract disease, a urinary tract disease, a digestive disorder, and a disease associated with severe pain or conditions of pain.

14. (previously presented): The method of claim 13, wherein the disease is a gastrointestinal tract disease selected from the group consisting of a functional gastrointestinal disease, a functional gastroduodenal disease, a functional intestinal disease, a chronic motility disorder, an inflammatory gastrointestinal tract disease, and a non-inflammatory gastrointestinal tract disease.

15. (currently amended): The method of claim 13 ~~[[12]]~~, wherein the disease is dyspepsia.

16. (currently amended): The method of claim 13 [[12]], wherein the disease is irritable bowel syndrome.

17. (currently amended): The method of claim 13 [[12]], wherein the disease is post-operative ileus.

18. (previously presented): The method of claim 13, wherein the disease is a urinary tract disease selected from the group consisting of an inflammatory and a non-inflammatory urinary tract disease, and irritable bladder syndrome.

19. (currently amended): ~~Process~~ A method for the preparation manufacture of a pharmaceutical composition, comprising:

formulating characterised in that ingredients of the composition, wherein the ingredients comprise at least one or more derivatives according to Claim 1, or a salt, solvate, or prodrug thereof, and at least one or more further compounds selected from excipients, adjuvants and pharmaceutical active ingredients which are different from such derivatives;

mixing the ingredients to homogeneity; and ~~are converted, using one or more mechanical process steps, into a pharmaceutical composition~~

preparing the mixture in a form ~~which is suitable as dosage form~~ for administration to patients.


20. (previously presented): Pharmaceutical composition, characterised in that it comprises at least one derivative according to Claim 1.

21. (original): Pharmaceutical composition according to Claim 20, characterised in that it comprises at least one further pharmaceutical active ingredient.

22. (original): Pharmaceutical composition according to Claim 21, characterised in that the further active ingredient is selected from phenylpropanolamine, cathine, sibutramine, amfepramone, ephedrine and norpseudoephedrine.

23. (previously presented): Process for the preparation of a derivative according to Claim I, in which

- a) a compound of the formula II



in which

L^1 is H or a metal ion;

- b) is reacted with a compound of the formula III



in which

L^2 is a leaving group, and

R^1 is selected from substituted or unsubstituted acyl radicals having from 1 to 12 carbon atoms, alkyl radicals derived from polyhydroxymonocarboxylic acids by removal of a hydroxyl group, sulfonic acid groups, phosphonic acid groups and nitro groups or, if

R^1 contains one or more functional groups in addition to the group L^2 , a derivative of R^1 which is provided fully or partly with protecting groups,

- c) any protecting groups present are cleaved off, if desired the compound of the formula I is isolated, and optionally
- d) the resultant compound of the formula I is converted into one of its salts by treatment with an acid or base, and, if desired, the salt is isolated.

24. (previously presented): A pharmaceutical composition comprising the derivative according to claim 10, or a salt, solvate, and prodrug thereof.